慢性阻塞性肺疾病稳定期的治疗

慢性阻塞性肺疾病（chronic obstructive pulmonary diseases,COPD）稳定期指患者咳嗽、咳痰、气短等症状稳定或症状轻微。沈阳部分社区40岁以上人群调查表明稳定期患者占COPD的86．62％,稳定期患者平均每人每年急性加重1～2次,     

Gastroesophageal Reflux Disease and Chronic Cough

Gastroesophageal reflux disease (GERD) is a common cause of unexplained chronic cough. This article reviews important clinical considerations regarding association, diagnosis, and treatment of GERD in the setting of chronic unexplained cough.     

Curry Induces Acid Reflux and Symptoms in Gastroesophageal Reflux Disease

Background  

There are limited data on the effect of curry on gastroesophageal reflux disease (GERD). Our objective was to study the effects of curry on GERD.     

Association of Lung Function Genes with Chronic Obstructive Pulmonary Disease

Background

Spirometric measurements of pulmonary function are important in diagnosing and determining the severity of chronic obstructive pulmonary disease (COPD). We performed this study to determine whether candidate genes identified in genome-wide association studies of spirometric measurements were associated with COPD and if they interacted with smoking intensity.

Methods

The current analysis included 1,000 COPD subjects and 1,000 controls recruited from 24 hospital-based pulmonary clinics. Thirteen SNPs, chosen based on genome-wide association studies of spirometric measurements in the Korean population cohorts, were genotyped. Genetic association tests were performed, adjusting for age, sex, and smoking intensity, using models including a SNP-by-smoking interaction term.

Results

PID1 and FAM13A were significantly associated with COPD susceptibility. There were also significant interactions between SNPs in ACN9 and FAM13A and smoking pack-years, and an association of ACN9 with COPD in the lowest smoking tertile. The risk allele of FAM13A was associated with increased expression of FAM13A in the lung.

Conclusions

We have validated associations of FAM13A and PID1 with COPD. ACN9 showed significant interaction with smoking and is a potential candidate gene for COPD. Significant associations of genetic variants of FAM13A with gene expression levels suggest that the associated loci may act as genetic regulatory elements for FAM13A gene expression.     

噻托溴胺对慢性阻塞性肺疾病稳定期患者生存质量的评价

目的观察中度慢性阻塞性肺疾病(COPD)稳定期吸入噻托溴胺的临床疗效。方法将40例中度COPD(Ⅱ～Ⅲ级)稳定期患者随机分为2组,治疗组(噻托溴铵组)(n=20,思力华,Boehinger Ingelheim,18ug,1次/d,早晨给药)和对照组(n=20,按需使用短效抗胆碱能支气管扩张剂),整个观察期为1年,观察2组用药3个月、6个月和1年后肺功能的变化以及StGeorge′s呼吸问卷(SGRQ)等情况,通过6min步行试验(6MWT)观察运动耐力的变化以及随访3～12个月急性加重的例次及住院例次。结果用药3个月后治疗组FEV1、FVC、FEV1/FVC及FEV1占预计值(%)比对照组明显改善,2组比较差异有显著性(P0.05),治疗组运动耐力(6MWT)增加,SGRQ评分比较治疗组明显下降,随访3～12个月治疗组急性加重例次明显减少,与对照组比较差异有显著性(P0.05);治疗组用药后3个月、6个月和1年后肺功能比较无显著差异(P0.05)。结论吸入噻托溴胺可以改善稳定期(Ⅱ～Ⅲ级)COPD患者肺功能与运动耐力,减少急性加重的发作,改善生活质量,不良反应少,使用方便,值得临床广泛推广。     

噻托溴铵治疗慢性阻塞性肺疾病稳定期的临床疗效研究

目的探讨噻托溴铵治疗慢性阻塞性肺疾病(COPD)稳定期的临床疗效。方法选取2012年在南昌大学第一附属医院进行治疗的COPD稳定期患者200例,随机分为治疗组和对照组,各100例。对照组患者给予COPD常规治疗,治疗组患者在COPD常规治疗基础上给予噻托溴铵治疗,均连续治疗8周后随访6个月。比较两组患者治疗前后肺功能指标,包括:第一秒用力呼气末容积(FEV1)、用力肺活量(FVC)及FEV1/FVC比值;观察两组患者治疗前和随访3、6个月时呼吸困难指数(m MRC)和6分钟步行距离(6MWT)及治疗期间不良反应发生情况。结果两组患者治疗前FEV1、FVC及FEV1/FVC比值比较,差异无统计学意义(P0.05);治疗组患者治疗后FEV1、FVC及FEV1/FVC比值均高于对照组(P0.05)。两组患者治疗前m MRC和6MWT比较,差异无统计学意义(P0.05);治疗组患者随访3个月、6个月时m MRC低于对照组,6MWT长于对照组(P0.05)。治疗组患者不良反应发生率为7%,与对照组的8%比较,差异无统计学意义(P0.05)。结论噻托溴铵能改善COPD稳定期患者肺功能,缓解临床症状,提升运动耐量,且安全性良好。     

胃食管阀瓣在胃食管反流病中的分布及其与症状的相关性

背景：近年我国胃食管反流病（GERD）的发生率不断升高,胃食管阎瓣（GEFV）分级对评估GERD有重要作用。目的：探讨GEFV在GERD中的分布特征及其与患者症状的关系。方法：选取2010年1～12月聊城市人民医院行胃镜检查发现的343例糜烂性食管炎（EE）、483例非糜烂性反流病（NERD）和99例Barrett食管（BE）患者,记录GEFV的Hill分级,采用GERD症状评定量表（GSAS）记录症状频率、严重度评分。比较GERD各型中GEFV的分布及其与症状频率、严重度评分的关系。结果：异常GEV多见于男性、高龄、超重和食管裂孔疝患者。随着EE的Los Angeles分级增加,异常GEV的发生率增加（P=0.002）;GEFV分级在EE、NERD和BE组间的分布无明显差异（P=0.612）：与正常GEFV组相比,异常GEFV组GERD的症状频率评分明显增高（P〈0.05）,而症状严重度评分无明显差异（P〉0.05）。多重线性回归分析显示症状频率评分与年龄、GEFV分级和GERD类型相关（P〈0.05）,症状严重度评分与年龄、GERD类型相关（P〈0.05）。结论：GEFV分级在GERD各亚型中的分布无明显差异,而与GERD症状频率相关。     

信必可都保干粉吸入治疗慢性阻塞性肺疾病的疗效评价

目的 观察信必可都保干粉(信必可)吸入治疗慢性阻塞性肺疾病(COPD)稳定期患者的疗效.方法 对40例处于稳定期的中、重度COPD患者在常规治疗基础上,给予吸入信必可(160.0/4.5ug),每次l吸,2次/d,记录治疗前、后肺功能及6分钟步行距离、住院次数、呼吸困难变化等,治疗前后进行比较.结果 治疗后肺功能指标、临床症状改善情况、6分钟步行距离、住院次数等均明显优于治疗前(P＜0.05).结论 对于稳定期COPD患者,信必可能减轻临床症状,明显改善肺功能,降低住院次数,提高生活质量.     

Prevalence and Impact of Symptoms Suggestive of Gastroesophageal Reflux Disease

Few studies have focused on the impact ofgastroesophageal reflux disease on general health and onwork absenteeism. Our aim was to evaluate the prevalenceand severity of symptoms suggestive of gastroesophageal reflux disease in two samples of Italianemployees. We interviewed 424 subjects of S. MatteoHospital staff and 344 subjects of the Military Factoryof Pavia regarding the frequency and severity ofheartburn and acid regurgitation during the last 12months. Subjects were specifically asked whethersymptoms interfered with the quality of work activitiesor determined work absenteeism. In all, 91% of eligible subjects responded. The prevalence rate per 100of any heartburn or regurgitation experienced at leastmonthly was 21. This value increased to 45% taking intoconsideration symptoms experienced occasionally. Mild or moderate symptoms were more frequentthan severe symptoms (P < 0.001). Only 2.6% ofsubjects answered that symptoms have a negativeinfluence on the quality of their work. No workabsenteeism was recorded. The study confirms that typicalgastroesophageal reflux symptoms are common conditions,but mainly of mild or moderate degree.     

Gastroesophageal Reflux Disease Increases Susceptibility to Nontuberculous Mycobacterial Pulmonary Disease

1. Download : Download high-res image (268KB)
2. Download : Download full-size image

     

Economic Impact of Pulmonary Drugs on Direct Costs of Stable Chronic Obstructive Pulmonary Disease

Question of the Study. To assess the impact of prescribing pulmonary drugs according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines on direct costs in stable chronic obstructive pulmonary disease (COPD). Patients and Methods. A total of 560 ambulatory COPD patients completed a specific questionnaire that included data regarding drug therapy. Severity was graded according to the British Thoracic Society (BTS) criteria and appropriateness of pharmacological treatment according to GOLD guidelines. Results. Annual direct costs were 1,657 EUR in stage I, 2,425 EUR in stage II, and 3,303 EUR in stage III. The mean direct costs was 2,061 EUR (38% corresponded to drug therapy). Medication accounted for 43%, 37.6%, and 28.4% of total direct costs for stage I, II, and III, respectively. Inhaled steroids and long‐acting β₂‐agonists accounted for 78%, 76%, and 75% of total drugs costs in stages I, II, and III, respectively. Drug therapy which was not in accordance with guidelines accounted for 78.7% and 54% of total drug costs in stages I and II, respectively. Most patients with severe disease were treated adequately. Answer to the Question. Pharmacologic treatment has a great impact on direct medical costs in stable COPD. According to GOLD guidelines, patients with mild or moderate COPD are frequently treated with nonrecommended drugs.     

Nonalcoholic Fatty Liver Disease Increases Risk for Gastroesophageal Reflux Symptoms

Background

Nonalcoholic fatty liver disease (NAFLD) is now recognized as a leading cause of liver dysfunction. Gastroesophageal reflux disease (GERD) is a common disorder causing symptoms that often impair patients’ quality of life. In recent years, the prevalence of both these diseases has increased, partially overlapping the rise of metabolic disorders.

Aims

We investigated whether a relation does exist between NAFLD and GERD symptoms.

Methods

Cross-sectional study among 206 outpatients diagnosed with NAFLD and 183 controls. We collected clinical and laboratory data, assessed severity and frequency of GERD symptoms and the esophageal endoscopic pattern.

Results

The prevalence of GERD symptoms was higher in NAFLD patients than controls (61.2 vs. 27.9 %, p < 0.001). We found a positive association between NAFLD and the experiencing of heartburn, regurgitation and belching. GERD symptoms were related to body mass index (BMI) and metabolic syndrome (MetS); a strong association persisted after adjustment for all the covariates (adjusted OR 3.49, 95 CI % 2.24–5.44, p < 0.001).

Conclusions

Our data show that the prevalence of GERD typical symptoms is higher in patients with NAFLD. GERD was associated with higher BMI and MetS, but not with age and diabetes type 2. NAFLD remained strongly associated with GERD, independently of a coexisting MetS status. Consistent with these findings, MetS can be considered a shared background, but cannot completely explain this correlation. We suggest NAFLD as an independent risk factor for GERD symptoms.